Search results for " Myocardial"

showing 10 items of 305 documents

Type 2 Myocardial Infarction: A Geriatric Population-based Model of Pathogenesis

2019

International audience; Distinction between type 2 myocardial infarction (T2MI), defined as an imbalance between oxygen supply and demand without atherothrombosis, and type 1 myocardial infarction (T1MI), due to plaque disruption, is often a clinical challenge in frail elderly patients. We aimed to identify the characteristics and underlying causes of T2MI using a comprehensive geriatric approach. From a multicentre population-based prospective study in coronary care units, we adjudicated 4572 consecutive patients hospitalized for an acute T1MI or T2MI, according to the 3rd universal definition and a prespecified geriatric model of T2MI pathogenesis. In total, 3710 (81%) had T1MI and 862 (1…

0301 basic medicineRiskmedicine.medical_specialtyrespiratory tract infectionPopulationOutcomesLower riskOrginal ArticlePathology and Forensic Medicinetype 2 myocardial infarctionPathogenesis03 medical and health sciences0302 clinical medicineInternal medicineMedicineDiseaseMyocardial infarctionMortalityProspective cohort studyeducationFeatureseducation.field_of_studybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyVaccinationRespiratory infectionaortic stenosisCell Biologymedicine.diseaseanemia3. Good healthStenosis030104 developmental biologyHeart failureCardiologyNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgerytachyarrhythmia pathophysiology
researchProduct

Galectin-3 in acute coronary syndrome

2017

Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This art…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeAcute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical BiochemistryPrognosiGalectinsGalectin 3Clinical BiochemistryMyocardial InfarctionDisease030204 cardiovascular system & hematologyAMI03 medical and health sciences0302 clinical medicineFibrosismedicineHumansGalectin-3Myocardial infarctionIntensive care medicineHeart FailureEvidence-Based Medicinebiologybusiness.industryGold standardGeneral MedicineBlood ProteinsBiomarkermedicine.diseaseAtherosclerosisPrognosisTroponin030104 developmental biologyGalectin-3Heart failureAtherosclerosibiology.proteinAcute coronary syndromebusinessBiomarkersHuman
researchProduct

Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: A Systematic Review for Post Mortem Applications

2020

The complement system has a significant role in myocardial ischemia/reperfusion injury, being responsible for cell lysis and amplification of inflammatory response. In this context, several studies highlight that terminal complement complex C5b-9, also known as the membrane attack complex (MAC), is a significant contributor. The MAC functions were studied by many researchers analyzing the characteristics of its activation in myocardial infarction. Here, a systematic literature review was reported to evaluate the principal features, advantages, and limits (regarding the application) of complement components and MAC in post mortem settings to perform the diagnosis of myocardial ischemia/infar…

0301 basic medicinemedicine.medical_specialtyForensic pathologyClinical BiochemistryInfarctionContext (language use)Reviewischemia/reperfusion injury03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicine030216 legal & forensic medicineMyocardial infarctioncomplement systemlcsh:R5-920business.industryC5b-9schemia/reperfusion injuryforensic pathologymedicine.diseaseComplement systempost mortem investigation030104 developmental biologymyocardial infarctionInclusion and exclusion criteriaCardiologyC5b-9; complement system; forensic pathology; ischemia/reperfusion injury; myocardial infarction; post mortem investigationbusinessComplement membrane attack complexlcsh:Medicine (General)Reperfusion injury
researchProduct

Unraveling the thread of uncontrolled immune response in COVID-19 and STEMI: an emerging need for knowledge sharing

2021

The outbreak of severe acute respiratory syndrome coronavirus 2 that first emerged in Wuhan in December 2019 has resulted in the devastating pandemic of coronavirus disease 2019, creating an emerging need for knowledge sharing. Meanwhile, myocardial infarction is and will probably remain the foremost cause of death in the Western world throughout the coming decades. Severe deregulation of the immune system can unnecessarily expand the inflammatory response and participate in target and multiple organ failure, in infection but also in critical illness. Indeed, the course and fate of inflammatory cells observed in severe ST-elevation myocardial infarction (neutrophilia, monocytosis, and lymp…

0301 basic medicinemedicine.medical_specialtyPhysiologyReview030204 cardiovascular system & hematologycoronavirus disease 201903 medical and health sciences0302 clinical medicineImmune systemMonocytosisImmunityPhysiology (medical)PandemicHumansMedicineIntensive care medicineCause of deathInflammationInnate immune systembusiness.industryCOVID-19Acquired immune systemmedicine.diseaseimmunityKnowledge sharingmyocardial infarction030104 developmental biologyImmune SystemST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Exploring the association between extra-cardiac troponin elevations and risk of future mortality

2019

Although the measurement of cardiac troponin I (cTnI) and T (cTnT) has now become the cornerstone for diagnosing cardiac injury, both ischemic and non-ischemic, recent evidence has become available that many patients display extra-cardiac causes of cTn elevations and carry a considerably enhanced risk of future mortality. The current literature data suggests that cTn elevations may be equally common in patients with cardiac and extra-cardiac diseases. Among the latter cohort of patients, the leading extra-cardiac diseases which may be responsible for either cTnI or cTnT elevations include infectious diseases/sepsis, pulmonary disorders, renal failure, malignancy, as well as gastrointestinal…

030213 general clinical medicinemedicine.medical_specialtycardiac injuryClinical Biochemistry030209 endocrinology & metabolismSepsislcsh:Biochemistry03 medical and health sciences0302 clinical medicineTroponin complexInternal medicineTroponin IOpinion Papermedicinelcsh:QD415-436Myocardial infarctionStrokeCause of deathbiologybusiness.industrytroponinBiochemistry (medical)medicine.diseaseTroponinmortalitymyocardial infarctionHeart failurecardiac injury mortality myocardial infarction troponinCardiologybiology.proteincardiovascular systembusinessJournal of Medical Biochemistry
researchProduct

Studies to Elucidate the Mechanism of Cardio Protective and Hypotensive Activities of Anogeissus acuminata (Roxb. ex DC.) in Rodents

2020

Anogeissus acuminata (Roxb. ex DC.) is a folkloric medicinal plant in Asia

1Pharmaceutical Scienceacute myocardial infarction 3030204 cardiovascular system & hematologyPharmacologyCreatineAnalytical ChemistryNitric oxidelcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinevasorelaxant 4lcsh:Organic chemistryIn vivoDrug DiscoveryRenin–angiotensin systemleft ventricular hypertrophy 2Physical and Theoretical ChemistryCyclic guanosine monophosphate030304 developmental biology0303 health sciencesbiologyOrganic ChemistryAngiotensin-converting enzymehypotensivechemistryChemistry (miscellaneous)biology.proteinMolecular MedicineCreatine kinasehistopathology 6cardio relaxant 5Ex vivoMolecules
researchProduct

Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe

2020

We compared the ST elevation myocardial infarction (STEMI) incidence during COVID-19 pandemic (March 2020) to January-February 2020 and to same time period in earlier years 2017-2019 in five Nordic-Baltic tertiary centers. During 2017-2019, there were no marked differences in STEMI incidence between January, February and March. During 2020, there was an average drop of 32% in STEMI incidence in March. The isolation measures may decrease the risk for respiratory virus infection and contribute to the lower STEMI incidence and that we might benefit from firmer suggestions on hand hygiene and social distancing during flu season at least among high-risk individuals.

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)media_common.quotation_subject030204 cardiovascular system & hematologyScandinavian and Nordic CountriesTertiary Care Centers03 medical and health sciences0302 clinical medicineSt elevation myocardial infarctionHygieneRespiratory virus infectionPandemicFlu seasonMedicineHumanscardiovascular diseases030212 general & internal medicinemedia_commonRetrospective Studiesbusiness.industryIncidence (epidemiology)IncidenceCOVID-19Latvia3. Good healthsurgical procedures operativeST-elevation myocardial infarctionincidenceST Elevation Myocardial InfarctionbusinessCardiology and Cardiovascular MedicineDemography
researchProduct

Angiotensin II dependent cardiac remodeling in the eel Anguilla anguilla involves the NOS/NO system

2017

Angiotensin II (AngII), the principal effector of the Renin-Angiotensin System (RAS), plays an important role in controlling mammalian cardiac morpho-functional remodelling. In the eel Anguilla anguilla, one month administration of AngII improves cardiac performance and influences the expression and localization of molecules which regulate cell growth. To deeper investigate the morpho-functional chronic influences of AngII on the eel heart and the molecular mechanisms involved, freshwater eels (A. anguilla) were intraperitoneally injected for 2 months with AngII (1 nmol g BW-1). Then the isolated hearts were subjected to morphological and western blotting analyses, and nitrite measurements.…

AT(2) receptor; ERK(1-2); Hsp90; Myocardial growth; NOSTRIN0301 basic medicineMAPK/ERK pathwayCancer ResearchPhysiologyClinical Biochemistry030204 cardiovascular system & hematologyBiochemistrychemistry.chemical_compound0302 clinical medicineEnosMyocardial growthReceptorMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Receptors AngiotensinVentricular RemodelingAngiotensin IIHeartNitric oxide synthaseERKmedicine.anatomical_structurecardiovascular systemCollagenmedicine.medical_specialtyEndotheliumHeart VentriclesHsp90BiologyNitric OxideNitric oxide03 medical and health sciencesInternal medicinemedicineAnimalsHSP90 Heat-Shock ProteinsVentricular remodelingAT receptorNitritesERK(1-2)Anguillamedicine.diseasebiology.organism_classificationNOSTRINAngiotensin II030104 developmental biologyEndocrinologychemistryAT(2) receptorbiology.proteinNitric Oxide SynthaseProto-Oncogene Proteins c-akt
researchProduct

TROMBECTOMIA INTRACORONARICA CON NeVA STENT RETRIEVER IN PAZIENTI AFFETTI DA SINDROME CORONARICA ACUTA: ESPERIENZA MULTICENTRICA FIRST-IN-MEN

2021

Acute Myocardial Infarction Coronary ThrombectomySettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

2021

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required i…

Acute coronary syndromemedicine.medical_specialtyacute coronary syndrome; cardiogenic shock; glycoprotein IIb/IIIa receptor inhibitors; myocardial infarction; percutaneous coronary interventionmedicine.medical_treatmentArticleacute coronary syndromeInternal medicineAngioplastyRisk of mortalityMedicineMyocardial infarctionAdverse effectbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseaseglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionConventional PCICardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct